Multiple Myeloma

Newly Diagnosed

Criteria to qualify for this study: Drug used in study:
  • Must have measurable disease - Serum M Protein ≥ 0.5 g/dL
  • Urine M-Protein ≥ 200 mg/24hr
  • Involved FLC level  ≥ 10 mg/dl & FLC ratio is abnormal
  • ANC  ≥ 1000, PLT  ≥ 75, HGB  ≥ 7

SCRI MM-43 - Onyx

Phase 1b/2, Multicenter, Open-Label Study of Oprozomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. OPZ003

 

 

 

 

 

 
 


Relapsed or Refactory

Criteria to qualify for this study: Drug used in study:
  • —Patient must have received 2 prior therapies which must have included boretzomib and lenalidomide or thalidomede (alone or in combination) / No prior history of carfilzomib exposure unless subject has had at leaxt a PR to carfilzomib therapy

MM 47 SCRI Onyx

A Phase I b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects                                              

COMING SOON

 

 

 

 

 

 

Criteria to qualify for this study: Drug used in study:
  • Must have had at least two previous tretment regimens
  • Patients refractory to bortezomib are excluded
  • Patients with active GI issues are excluded.       

MM 50  SCRI

Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma with a Dose-Finding Lead-In                                             

COMING SOON

 

 

 

 

 

 

 

Criteria to qualify for this study: Drug used in study:
  • Serum M-protein level of at least 1.0 and/or urine M-protein  level of at least 200 mg/24hr.
  • Patient must have received at least 2 prior therapies which must  2 cycles must have included bortezomib and 2 cycles must have included lenalidomide
  • Disease must be refractory to a carfilzomib and/or a pomalidomide-containg regimen.

SCRI  MM-53 ARRAY-520-215

A Multicenter Phase 2 Study of Single-Agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

 

 

 

 

 

 

 

Criteria to qualify for this study: Drug used in study:
  • Must have had at least two previous tretment regimens
  • Patients refractory to bortezomib are excluded
  • Patients with active GI issues are excluded.       

MM58  SCRI  Janssen

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexametasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Inelibgible for High Dose Therapy                                          

COMING SOON

 

 

 

 

 

 

 

Criteria to qualify for this study: Drug used in study:

  • Patients must have no available approved therapies that confer clinical benefit  /  Peripheral blood blasé count must be 30 or less  / No APL  / DLCO less than 50% of predicted not allowed  /  No CNS disease

SCRI  HEMREF 37 CX-839-002

A Phase 1 Study  of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminiase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies

 

 

 

 

 

 

 

Criteria to qualify for this study: Drug used in study:
  • Serum M-protein level of at least 1.0 and/or urine M-protein level of at least 200 mg/24hr.
  • Patients requiring anticoagulation with warfarin are excluded
  • PLT must be at least 75
  • ANC must be at least 750
  • —Hemoglobin must be at least 8

SCRI  MM-51

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibruitnib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

 

 

 

 

 

 

 


Post Transplant

Criteria to qualify for this study: Drug used in study:

  • Must have had transplant due to high-risk features  /  Engraftment of neutrophils ANC greater than 1000  / Engraftment of platelets, PLT greater than 60  /  Achievement of at least a PR prior to transplant  /  Absence of GI symptoms  /  Cord blood or haplo transplant not allowed

MM 42 SCRI Millennium

Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD)